©2015 MFMER | slide-1 Introduction to Immuno-Oncology Keith L. Knutson, Ph.D. Professor of Immunology Community Oncology Conference 2.0 April 23-24, 2015.

©2015 MFMER | slide-1

Introduction to Immuno-Oncology

Keith L. Knutson, Ph.D.Professor of ImmunologyCommunity Oncology Conference 2.0April 23-24, 2015

©2015 MFMER | slide-2

Cells of the immune system

All cellular elements of the blood are derived from a single pluripotent hematopoietic stem cell

©2015 MFMER | slide-3

Phagocytes

MonocytesDCP

©2015 MFMER | slide-4

Polymorpho-nuclear

leukocytes

All (except maybe mast cells) are derived from the common myeloid precursor

©2015 MFMER | slide-5

Natural Killer Cells

INNATE

Both are derived from the common lymphoid precursor

Lymphocytes

Antigen-Specific

LymphocytesADAPTIVE

©2015 MFMER | slide-6

Schematic Structure of Antigen Receptors

©2015 MFMER | slide-7

Antigens are recognized by the immune response while epitopes are sites within antigens

©2015 MFMER | slide-8

Antibodies and T cell receptors recognize antigen by different

mechanisms

©2015 MFMER | slide-9

Antibody dependent cellular cytotoxicity

Antibodies have multiple functions

Antibody mediated opsonizationSignal interferenceBlockade of uptake

Shuttle

©2015 MFMER | slide-10

There are a variety of T cell subsets

©2015 MFMER | slide-11

Oncogenesis

proto-oncogenes

tumorsuppressorgenes

oncogenes

Carcinogenresults in mutation

dysfunctional tumor suppressorgenes

inheriteddefect

increased GF

increased GF receptors

exaggerated response to GF

loss of ability torepair damaged cells or induceapoptosis

Increased growth

Virus introduces oncogenes

©2015 MFMER | slide-12

Tumor Antigen Classifications

• Tumor-specific antigens– Ras– p53– BCR-Abl– Viral antigens– Mis-splice variants

• Cancer-Testis antigen– MAGE (1st cloned tumor

antigen)– NY-ESO

• Differentiation antigens– Tyrosinase– MART-1

• Overexpressed antigens– HER-2/neu– hTERT

©2015 MFMER | slide-13

Paradoxical roles of the immune system in cancer

development1. The key functions of the mammalian immune system:

(1) Protect from infectious pathogens(2) Monitor tissue homeostasis => Eliminate damaged

cells (e.g. tumor cells) and induce wound healing.

2. Mechanisms against cancer development: (1) Cellular immunity- T, NK, & Other innate immune cells(2) Humoral immunity- Cytokines, Abs, etc.

3. Mechanisms promoting cancer development: (1) Inflammation => Angiogenesis & Tissue remodeling(2) Enhance survival pathways (NF-kB activation)(3) Suppression of anti-tumor immune responses

©2015 MFMER | slide-14

The complex relationship between the immune system

and cancers1. Adaptive and innate immune cells regulate tissue

homeostasis and efficient wound healing

2. Altered interactions between adaptive and innate immune cells can lead to “chronic inflammatory disorders”.

3. Chronic inflammatory conditions enhance a predisposition to cancer development.

4. In cancers, an abundance of infiltrating innate immune cells (e.g. macrophages, mast cells, and neutrophils) correlates with increased angiogenesis and/or poor prognosis.

©2015 MFMER | slide-15

Association of inflammation with cancers

©2015 MFMER | slide-16

Acute vs. Chronic Inflammation: Role in Cancer Pathology

©2015 MFMER | slide-17

Inflammation causes genomic damage through reactive oxygen

and nitrogen

©2015 MFMER | slide-18

Inflammation elevates cytokines that activate transcription factors which promote tumor formation and

progression.

©2015 MFMER | slide-19

Inflammation induces immune suppressive cells which prevent

adaptive cellular immunity

©2015 MFMER | slide-20

Science 2013;339:286-291

Malignant cells foster development of wound healing responses

©2015 MFMER | slide-21

Preventing Tumor-inducing Inflammation

• Life style changes: lose weight, quit smoking, quit drinking.

• Non-steroidal anti-inflammatories: colorectal, bladder, ovarian.

• Vaccination: HBV, MUC1

• Phytochemicals: Variety of inhibitors (Natural Cox and Stat3 inhibitors).

Gut 2010;59:1670-1679

©2015 MFMER | slide-22

Science 2013;339:286-291

Converting chronic to

acute inflammatio

n

©2015 MFMER | slide-23

Science 2013;339:286-291

Reversing Tumor-Associated Chronic

Inflammation

• Adoptive Therapies• T cells• Cytokines

• Vaccines• Combination

approaches

• Viruses to induce acute inflammation

• Checkpoint blockade

©2015 MFMER | slide-24

• Reconstituting humoral immunity

• Humanization of mouse monoclonals

• Mechanisms of action• ADCC• Complement• Signal enhancer/inhibitor• Enhances acute immunity

Monoclonal antibody therapy

©2015 MFMER | slide-25

Mocellin et al, Cochrane Database of Systemic Reviews 2013;DOI10.1002/14651858

Meta-analysis of interferon impact on overall survival

©2015 MFMER | slide-26

Humanizing monoclonal antibodiesMonoclonal antibody therapy

©2015 MFMER | slide-27

MAb Name Trade Name Used to Treat: Target

Rituximab Rituxan Non-Hodgkinlymphoma CD20

Trastuzumab Herceptin Breast cancer HER-2/neu

Gemtuzumab ozogamicin* Mylotarg

AcuteMyelogenousleukemia (AML)

CD33

Alemtuzumab CampathChronicLymphocyticleukemia (CLL)

CD52

Ibritumomab tiuxetan* Zevalin Non-Hodgkin

lymphoma CD20

Tositumomab* Bexxar Non-Hodgkinlymphoma CD20

Cetuximab Erbitux Colorectal cancer EGFR

Bevacizumab Avastin Colorectal cancer VEGF

FDA-Approved antibodies

©2015 MFMER | slide-28

HER2+ Breast Cancer Management

1st-line: chemo + trastuzumab

Metastatic Disease• Response 50-80%• Time to disease

progression ~ 11-14 mo

Adjuvant Setting• ~50% reduction in relapse• Best if used concurrently

with chemo.

©2015 MFMER | slide-29

Therapeutic Efficacy of Herceptin

New England Journal of Medicine

©2015 MFMER | slide-30

TIL Therapy

©2015 MFMER | slide-31

Current Opinion in Immunology

Tumor regression following T cell infusion

©2015 MFMER | slide-32

Current Opinion in Immunology

Survival of Patients Treated with TIL and IL-2

©2015 MFMER | slide-33

UveitisVitiligo

Autoimmunity Following Cell therapy

©2015 MFMER | slide-34

• Target suppressive molecules: anti-IL-10 antibodies

• Block key immune regulatory loops• Anti-CTLA-4 (checkpoint blockade)

• Block systemic and infiltrating regulatory T cells

• IL-2 immunotoxin• Anti-CD25 antibody

Blocking immune suppression

©2015 MFMER | slide-35

Checkpoint Blockade

©2015 MFMER | slide-36

©2015 MFMER | slide-37

Anti-CTLA-4 causes regressions of melanoma metastases

Klein O et al. Clin Cancer Res 2009;15:2507-2513

Lung met

Lymph node met

Chest wall met

©2015 MFMER | slide-38

Anti-PD-1 causes regressions of melanoma metastases

New England Journal of Medicine

©2015 MFMER | slide-39

Chimeric Antigen Receptor T cell Therapy